Schizophrenia is a complex chronic disorder is associated with significant functional impairment and high personal and social costs.
Sun, 24/05/2026 - 11:00
2 minSchizophrenia is a complex chronic disorder is associated with significant functional impairment and high personal and social costs.
cabecera_rovi_rocks_4.png
Schizophrenia is a complex chronic disorder is associated with significant functional impairment and high personal and social costs. Likewise it is compounded by a high rate of comorbidities, such as cardiovascular diseases, leading to isolation and a progressive worsening of the condition.
On 24 May, World Schizophrenia Day, we at ROVI would like to shine a spotlight on people, their wellbeing, and the importance of continuing to construct increasingly humane, accessible and recovery-oriented care.
A reality that requires attention
The latest data, gathered in the Global Burden of Disease Study 2021, provide a clear picture of the scale of the challenge: over 23.2 million people all over the world live with schizophrenia, representing around 0.3% of the global population. Global prevalence stands at 293.8 cases per 100,000 inhabitants, with 332.5 cases per 100,000 inhabitants in Spain. Beyond the figures, one of the main challenges in managing schizophrenia continues to be maintaining good treatment adherence, a key factor in reducing relapses and hospital readmissions that impair patients’ functioning and quality of life.
Our commitment: to support, research and improve
At ROVI, we maintain a sustained commitment to the research and development of innovative solutions in the mental health field. Our ISM® technology forms part of this effort and has led to developments that are already available in various markets.
At the same time, we continue to work on new formulations in research, with the aim of further expanding the options available in the future. This commitment involves continuing to research, collaborating with healthcare professionals, and always placing patients at the centre of our work.
Sources: GBD 2021 Schizophrenia Collaborators. The Global Burden of Schizophrenia: Findings from the 2021 Global Burden of Diseases, Injuries, and Risk Factors Study. Schizophrenia Bulletin Open, Volume 7, Issue 1, 2026, sgag012. Litman R, et al.
Personal and Social Functioning and Health-Related Quality of Life in Patients with Schizophrenia Treated with the Long-Acting Injectable Antipsychotic Risperidone ISM. Neuropsychiatric Disease and Treatment 2023:19 219–232.